To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future.
All of our revenue during the three months ended March 31, 2016 and 2015 has been derived from our collaboration agreements with Astellas and Biogen. Revenue was $1.2 million for the three months ended March 31, 2016, compared to $0.8 million for the three months ended March 31, 2015. The increase of $0.4 million was the result of an increase of $0.3 million of revenue recognized from our collaboration with Astellas and an increase of $0.1 million of revenue recognized from our collaboration with Biogen.

See: http://www.sec.gov/Archives/edgar/data/1445283/000119312516590536/d171953d10q.htm